Literature DB >> 2283509

31P NMR studies of enzyme-bound substrate complexes of yeast 3-phosphoglycerate kinase: III. Two ADP binding sites and their Mg(II) affinity; effects of vanadate and arsenate on enzymic complexes with ADP and 3-P-glycerate.

B D Ray1, J M Moore, B D Rao.   

Abstract

31P nuclear magnetic resonance (NMR) measurements (at 121.5 MHz and 5 degrees C) were made on complexes of 3-phosphoglycerate kinase with ADP and 3-P-glycerate. Addition of Mg(II) to E.ADP shifts the alpha-P signal downfield by 3.8 ppm such that the alpha-P signal superimposes that for beta-P(E.MgADP). Such a shift is atypical among the Mg(II)-nucleotide complexes with other ATP-utilizing enzymes. This shift allowed the determination that enzyme bound ADP is saturated with Mg(II) for [Mg(II)]/[ADP] = 3.0--similar to that reported for ATP complexes with this enzyme (B.D. Ray and B.D. Nageswara Rao, Biochemistry 27, 5574 (1988]. This parallel behavior suggests that ADP binds at two sites on the enzyme as does ATP with disparate Mg(II) affinities. 31P relaxation times in E.MnADP.vanadate.3-P-glycerate and E.CoADP.vanadate.3-P-glycerate complexes indicate that these are long-lived, tightly bound complexes. 31P chemical shift measurements on diamagnetic complexes (with Mg(II] revealed three signals in the 2-5 ppm region (attributable to 3-P-glycerate) only upon addition of all the components necessary to form the E.MgADP.vanadate.3-P-glycerate complex. Subsequent sequestration of Mg(II) from the complex with excess EDTA reversed the Mg(II) induced effects on the ADP signals but did not cause coalescence of the three signals seen in the 2-5 ppm region. Addition of excess sulfate to dissociate these complexes from the enzyme resulted in a single resonance of 3-P-glycerate. The use of arsenate in place of vanadate yielded very similar results. These results suggest that, in the presence of MgADP, vanadate or arsenate, and 3-P-glycerate, the enzyme catalyzed the formation of multiple structurally distinguishable complexes that are stable on the enzyme and labile off the enzyme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2283509     DOI: 10.1016/0162-0134(90)80039-z

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  6 in total

1.  Measurement of ADP-ATP exchange in relation to mitochondrial transmembrane potential and oxygen consumption.

Authors:  Christos Chinopoulos; Gergely Kiss; Hibiki Kawamata; Anatoly A Starkov
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Antagonistic binding of substrates to 3-phosphoglycerate kinase monitored by the fluorescent analogue 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate.

Authors:  M Vas; A Merli; G L Rossi
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

3.  A kinetic assay of mitochondrial ADP-ATP exchange rate in permeabilized cells.

Authors:  Hibiki Kawamata; Anatoly A Starkov; Giovanni Manfredi; Christos Chinopoulos
Journal:  Anal Biochem       Date:  2010-08-05       Impact factor: 3.365

4.  Solid-State NMR Reveals Asymmetric ATP Hydrolysis in the Multidrug ABC Transporter BmrA.

Authors:  Denis Lacabanne; Thomas Wiegand; Margot Di Cesare; Cédric Orelle; Matthias Ernst; Jean-Michel Jault; Beat H Meier; Anja Böckmann
Journal:  J Am Chem Soc       Date:  2022-07-01       Impact factor: 16.383

5.  Mg2+ affects the binding of ADP but not ATP to 3-phosphoglycerate kinase. Correlation between equilibrium dialysis binding and enzyme kinetic data.

Authors:  M Molnár; M Vas
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

6.  Alterations in voltage-sensing of the mitochondrial permeability transition pore in ANT1-deficient cells.

Authors:  Judit Doczi; Beata Torocsik; Andoni Echaniz-Laguna; Bénédicte Mousson de Camaret; Anatoly Starkov; Natalia Starkova; Aniko Gál; Mária J Molnár; Hibiki Kawamata; Giovanni Manfredi; Vera Adam-Vizi; Christos Chinopoulos
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.